Both GLP‐1 RAs and tirzepatide improve multiple cardiometabolic risk factors (waist circumference, systolic blood pressure, lipid profile) and quality of life parameters in people with obesity and/or diabetes [17]. Here, GLP1R is linked to obesity disorder.